Atomo Diagnostics (ASX:AT1) — Material Events
ASX:AT1 · 14 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Atomo Diagnostics Surges 121% Revenue, Expands Global Test PortfolioMedium
Atomo Diagnostics Q2 FY26 revenue surges 121%, secures key HIV and liver test orders, expands operations
28 Jan 2026
·Quarterly Report
·85
Atomo Diagnostics Accelerates US Growth Following FebriDx FDA CLIA WaiverMedium
Atomo Diagnostics Q3 FY26: Strong Sales Growth, US Market Expansion, $3M Capital Raise
28 Apr 2026
·Quarterly Activities and Cashflow Report
·85
Atomo Diagnostics Grows Revenue 41% While Narrowing Losses Amid Leadership ShiftMedium
Atomo Diagnostics reports 41% revenue growth, reduced loss, leadership change, and strategic expansion
31 Aug 2026
·Annual Report and Financial Results
·85
Atomo Diagnostics Advances FDA Bid and Boosts Capital in Q1 FY26Medium
Atomo Diagnostics advances FDA submissions, secures new capital, and reports Q1 FY26 revenue of $680k
29 Oct 2025
·Quarterly Activity Report
·85
Atomo Diagnostics Secures Exclusive Global License for Rapid Liver Function TestMedium
Atomo Diagnostics secures exclusive global license for novel rapid liver function test
20 Jan 2026
·Licensing Agreement Announcement
·80
Atomo Diagnostics Boosts FY26 Revenue 40% with Expanding HIV and OEM SalesMedium
Atomo Diagnostics reports 40% revenue growth and operational progress in Q4 FY26
23 July 2026
·Quarterly Report
·75
Atomo Diagnostics Secures $630k HIV Self-Test Order Backed by Government ProgramMedium
Atomo Diagnostics wins A$630k order for HIV Self-Tests supporting national government-funded program
6 Feb 2026
·ASX Announcement
·75
Atomo Diagnostics Lands A$416K HIV Self-Test Order Backed by Global FundMedium
Atomo Diagnostics Secures A$416,000 HIV Self-Test Order Funded by Global Fund
30 Jan 2026
·Contract Announcement
·75
Atomo Diagnostics Secures $502K HIV Self-Test Order for AfricaMedium
Atomo Diagnostics wins $502K HIV Self-Test order for African supply
15 Jan 2026
·ASX Announcement
·75
Atomo Diagnostics Clarifies Disclosure Timing After Lumos FDA Waiver Approval and Capital RaiseMedium
Atomo Diagnostics confirms compliance with ASX disclosure rules following Lumos FDA CLIA waiver approval and capital raise
17 Apr 2026
·ASX Aware Letter Response
·75
Atomo Diagnostics Names US-Based Dr Cheri Walker Interim CEO as Founder John Kelly Steps DownMedium
Atomo Diagnostics appoints Dr. Cheri Walker as interim CEO following John Kelly's departure
19 Aug 2026
·Executive Leadership Change
·70
Atomo Diagnostics Addresses Trading Surge Amid Lumos FDA UpdateMedium
Atomo Diagnostics denies undisclosed price-sensitive info amid trading surge; notes Lumos FDA update
25 Mar 2026
·Price Query Response
·50
Atomo Diagnostics Raises $44,500 in SPP with Options, Leaving $955,500 ShortfallMedium
Atomo Diagnostics Raises $44,500 via Share Purchase Plan with Options Issued
15 May 2026
·Capital Raising
·50
No articles in this tier for the last 12 months.
Market Mentions
10
- appeared in market wrap coverage
These are market wrap articles where Atomo Diagnostics (ASX:AT1) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026
22 Aug 2026
Healthcare Wrap - Week 30 (20 July -> 24 July) 2026
25 July 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026
18 Apr 2026
Market Wrap - Week 14 (30 Mar -> 3 Apr) 2026
4 Apr 2026
Healthcare Wrap - Week 14 (30 Mar -> 3 Apr) 2026
4 Apr 2026
Healthcare Wrap - Week 13 (23 Mar -> 27 Mar) 2026
28 Mar 2026
Healthcare Wrap - Week 6 (2 Feb -> 6 Feb) 2026
7 Feb 2026
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026
Healthcare Wrap - Week 4 (19 Jan -> 23 Jan) 2026
25 Jan 2026